Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.
BACKGROUND
There is increasing evidence that invasive fungal disease (IFD) is more likely to occur in non-neutropenic patients in critical care units. A number of randomised controlled trials (RCTs) have evaluated antifungal prophylaxis in non-neutropenic, critically ill patients, demonstrating a reduction in the risk of proven IFD and suggesting a reduction in mortality. It is necessary to establish a method to identify and target antifungal prophylaxis at those patients at highest risk of IFD, who stand to benefit most from any antifungal prophylaxis strategy.


OBJECTIVE
To develop and validate risk models to identify non-neutropenic, critically ill adult patients at high risk of invasive Candida infection, who would benefit from antifungal prophylaxis, and to assess the cost-effectiveness of targeting antifungal prophylaxis to high-risk patients based on these models.


METHODS
Systematic review, prospective data collection, statistical modelling, economic decision modelling and value of information analysis.


METHODS
Ninety-six UK adult general critical care units.


METHODS
Consecutive admissions to participating critical care units.


METHODS
None.


METHODS
Invasive fungal disease, defined as a blood culture or sample from a normally sterile site showing yeast/mould cells in a microbiological or histopathological report. For statistical and economic modelling, the primary outcome was invasive Candida infection, defined as IFD-positive for Candida species.


RESULTS
Systematic review: Thirteen articles exploring risk factors, risk models or clinical decision rules for IFD in critically ill adult patients were identified. Risk factors reported to be significantly associated with IFD were included in the final data set for the prospective data collection.


METHODS
Data were collected on 60,778 admissions between July 2009 and March 2011. Overall, 383 patients (0.6%) were admitted with or developed IFD. The majority of IFD patients (94%) were positive for Candida species. The most common site of infection was blood (55%). The incidence of IFD identified in unit was 4.7 cases per 1000 admissions, and for unit-acquired IFD was 3.2 cases per 1000 admissions. Statistical modelling: Risk models were developed at admission to the critical care unit, 24 hours and the end of calendar day 3. The risk model at admission had fair discrimination (c-index 0.705). Discrimination improved at 24 hours (c-index 0.823) and this was maintained at the end of calendar day 3 (c-index 0.835). There was a drop in model performance in the validation sample. Economic decision model: Irrespective of risk threshold, incremental quality-adjusted life-years of prophylaxis strategies compared with current practice were positive but small compared with the incremental costs. Incremental net benefits of each prophylaxis strategy compared with current practice were all negative. Cost-effectiveness acceptability curves showed that current practice was the strategy most likely to be cost-effective. Across all parameters in the decision model, results indicated that the value of further research for the whole population of interest might be high relative to the research costs.


CONCLUSIONS
The results of the Fungal Infection Risk Evaluation (FIRE) Study, derived from a highly representative sample of adult general critical care units across the UK, indicated a low incidence of IFD among non-neutropenic, critically ill adult patients. IFD was associated with substantially higher mortality, more intensive organ support and longer length of stay. Risk modelling produced simple risk models that provided acceptable discrimination for identifying patients at 'high risk' of invasive Candida infection. Results of the economic model suggested that the current most cost-effective treatment strategy for prophylactic use of systemic antifungal agents among non-neutropenic, critically ill adult patients admitted to NHS adult general critical care units is a strategy of no risk assessment and no antifungal prophylaxis.


BACKGROUND
Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Intensive Care National Audit and Research Centre, London, UK.
D
D
Harrison
H
H
Muskett
S
S
Harvey
R
R
Grieve
J
J
Shahin
K
K
Patel
Z
Z
Sadique
E
E
Allen
R
R
Dybowski
M
M
Jit
J
J
Edgeworth
C
C
Kibbler
R
R
Barnes
N
N
Soni
K
K
Rowan
D000935:Antifungal Agents / Q000008:administration & dosage* / Q000191:economics*; D058365:Candidiasis, Invasive / Q000453:epidemiology* / Q000517:prevention & control*; D018890:Chemoprevention; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000706:statistics & numerical data*; D020000:Decision Support Systems, Clinical; D006801:Humans; D015233:Models, Statistical; D009181:Mycoses / Q000453:epidemiology / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D013222:State Medicine; D006113:United Kingdom
D000935:Antifungal Agents